14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The accumulation of misfolded proteins in the human brain is one of the critical features of many neurodegenerative diseases, including Alzheimer's disease (AD). Assembles of beta-amyloid (Aβ) peptide—either soluble (oligomers) or insoluble (plaques) and of tau protein, which form neurofibrillary tangles, are the major hallmarks of AD. Chaperones and co-chaperones regulate protein folding and client maturation, but they also target misfolded or aggregated proteins for refolding or for degradation, mostly by the proteasome. They form an important line of defense against misfolded proteins and are part of the cellular quality control system. The heat shock protein (Hsp) family, particularly Hsp70 and Hsp90, plays a major part in this process and it is well-known to regulate protein misfolding in a variety of diseases, including tau levels and toxicity in AD. However, the role of Hsp90 in regulating protein misfolding is not yet fully understood. For example, knockdown of Hsp90 and its co-chaperones in a Caenorhabditis elegans model of Aβ misfolding leads to increased toxicity. On the other hand, the use of Hsp90 inhibitors in AD mouse models reduces Aβ toxicity, and normalizes synaptic function. Stress-inducible phosphoprotein 1 (STI1), an intracellular co-chaperone, mediates the transfer of clients from Hsp70 to Hsp90. Importantly, STI1 has been shown to regulate aggregation of amyloid-like proteins in yeast. In addition to its intracellular function, STI1 can be secreted by diverse cell types, including astrocytes and microglia and function as a neurotrophic ligand by triggering signaling via the cellular prion protein (PrP C). Extracellular STI1 can prevent Aβ toxic signaling by (i) interfering with Aβ binding to PrP C and (ii) triggering pro-survival signaling cascades. Interestingly, decreased levels of STI1 in C. elegans can also increase toxicity in an amyloid model. In this review, we will discuss the role of intracellular and extracellular STI1 and the Hsp70/Hsp90 chaperone network in mechanisms underlying protein misfolding in neurodegenerative diseases, with particular focus on AD.

          Related collections

          Most cited references208

          • Record: found
          • Abstract: found
          • Article: not found

          APP processing and synaptic function.

          A large body of evidence has implicated Abeta peptides and other derivatives of the amyloid precursor protein (APP) as central to the pathogenesis of Alzheimer's disease (AD). However, the functional relationship of APP and its proteolytic derivatives to neuronal electrophysiology is not known. Here, we show that neuronal activity modulates the formation and secretion of Abeta peptides in hippocampal slice neurons that overexpress APP. In turn, Abeta selectively depresses excitatory synaptic transmission onto neurons that overexpress APP, as well as nearby neurons that do not. This depression depends on NMDA-R activity and can be reversed by blockade of neuronal activity. Synaptic depression from excessive Abeta could contribute to cognitive decline during early AD. In addition, we propose that activity-dependent modulation of endogenous Abeta production may normally participate in a negative feedback that could keep neuronal hyperactivity in check. Disruption of this feedback system could contribute to disease progression in AD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cell-free formation of RNA granules: bound RNAs identify features and components of cellular assemblies.

            Cellular granules lacking boundary membranes harbor RNAs and their associated proteins and play diverse roles controlling the timing and location of protein synthesis. Formation of such granules was emulated by treatment of mouse brain extracts and human cell lysates with a biotinylated isoxazole (b-isox) chemical. Deep sequencing of the associated RNAs revealed an enrichment for mRNAs known to be recruited to neuronal granules used for dendritic transport and localized translation at synapses. Precipitated mRNAs contain extended 3' UTR sequences and an enrichment in binding sites for known granule-associated proteins. Hydrogels composed of the low complexity (LC) sequence domain of FUS recruited and retained the same mRNAs as were selectively precipitated by the b-isox chemical. Phosphorylation of the LC domain of FUS prevented hydrogel retention, offering a conceptual means of dynamic, signal-dependent control of RNA granule assembly. Copyright © 2012 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              A new puffing pattern induced by temperature shock and DNP in drosophila

              F Ritossa (1962)
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Neurosci
                Front Neurosci
                Front. Neurosci.
                Frontiers in Neuroscience
                Frontiers Media S.A.
                1662-4548
                1662-453X
                16 May 2017
                2017
                : 11
                : 254
                Affiliations
                [1] 1Molecular Medicine, Robarts Research Institute, University of Western Ontario London, ON, Canada
                [2] 2Program in Neuroscience, University of Western Ontario London, ON, Canada
                [3] 3Department of Biochemistry, University of Western Ontario London, ON, Canada
                [4] 4Department of Pathology and Laboratory Medicine, University of Western Ontario London, ON, Canada
                [5] 5Department of Physiology and Pharmacology, University of Western Ontario London, ON, Canada
                [6] 6Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario London, ON, Canada
                Author notes

                Edited by: Cintia Roodveldt, Centro Andaluz de Biología Molecular y Medicina Regenerativa, Spain

                Reviewed by: Toshihide Takeuchi, Osaka University, Japan; Janine Kirstein, Leibniz Institute for Molecular Pharmacology (FMP), Germany

                *Correspondence: Marco A. M. Prado mprado@ 123456robarts.ca

                This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience

                Article
                10.3389/fnins.2017.00254
                5433227
                28559789
                7d644aca-6c5e-4ea5-aa4d-7f07c5155f1c
                Copyright © 2017 Lackie, Maciejewski, Ostapchenko, Marques-Lopes, Choy, Duennwald, Prado and Prado.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 02 February 2017
                : 20 April 2017
                Page count
                Figures: 4, Tables: 1, Equations: 0, References: 293, Pages: 23, Words: 20788
                Funding
                Funded by: Canadian Institutes of Health Research 10.13039/501100000024
                Award ID: MOP 93651
                Award ID: MOP 136930
                Award ID: MOP 89919
                Award ID: MOP 126000
                Funded by: Natural Sciences and Engineering Research Council of Canada 10.13039/501100000038
                Award ID: 402524-2013
                Funded by: Canada Foundation for Innovation 10.13039/501100000196
                Categories
                Neuroscience
                Review

                Neurosciences
                stip1,hop,alzheimer's disease,tau,als,parkinson's disease,huntington's disease,tdp-43
                Neurosciences
                stip1, hop, alzheimer's disease, tau, als, parkinson's disease, huntington's disease, tdp-43

                Comments

                Comment on this article